Home
News Intelligence
Curatis Holding AG

Curatis Holding AG

Healthcare · Pharmaceuticals

SIX:CURN

Get alerts

Plain English summaries when Curatis Holding AG announces news.

Latest announcement

Financial results

Sep 21, 2026

Curatis reports 51% first-half revenue increase and progress on corticorelin programme

Curatis Holding AG reported higher first-half sales, improved its operating result and advanced development of corticorelin, including an exclusive Japan licence with Neupharma.

View summary and FAQs

Announcement Summary
Investor FAQs
Interactive Chat

Latest by type

Financial results: Curatis reports 51% first-half revenue increase and progress on corticorelin programme Sep 21, 2026
Financing: Curatis agrees CHF 3.0 million convertible placement, subject to closing conditions May 22, 2026

Announcements

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

About, from recent announcements

Curatis Holding AG specialises in the late stage development and commercialisation of drugs for rare diseases and specialty care, with a sales portfolio of 50 products and a pipeline of orphan and specialty drugs. It reported net sales from goods and services of CHF 7.9m for the first half of 2026, up 51%, and announced progress on its corticorelin (C-PTBE-01) programme, including an exclusive Japan licence with Neupharma and manufacturing activities. At its Annual General Meeting, shareholders approved all proposals of the Board of Directors, including the annual report and the financial year 2025, and re-elected the board members and compensation committee members.

Sources: 3 announcements

Curatis Holding AG

Get alerts

Curatis reports 51% first-half revenue increase and progress on corticorelin programme

Latest by type

Announcements

Curatis raises 2026 revenue growth guidance to approximately 40%

Curatis Holding AG shareholders approve all board proposals at AGM

Curatis agrees CHF 3.0 million convertible placement, subject to closing conditions

Curatis reports 2025 revenue growth as corticorelin programme advances

Curatis and Neupharma announce Japan licensing agreement for corticorelin